School of Medicine


Showing 341-360 of 479 Results

  • Matteo Santoro Pharm.D., Ph.D.

    Matteo Santoro Pharm.D., Ph.D.

    Postdoctoral Scholar, Pathology

    BioDr. Santoro joined Shamloo’s lab in March 2021 focusing his research on Parkinson’s disease, neuronal vulnerability, and identification of therapeutic markers in relation to α-synucleinopathies. Prior to his arrival at Stanford, he held a position as a clinical monitor at Syneos Health where he gained key knowledge needed to translate lab-based findings into clinical and commercial applications. Previously, Dr. Santoro held a postdoctoral position at the University of Aberdeen (Scotland, UK) working on amyloid-beta extracts from Alzheimer’s disease patients. During his postdoctoral research, Dr. Santoro designed and optimized a cost-effective and rapid assay for the measurement of toxic amyloid-beta species in human biofluids. In 2017, he obtained his Ph.D. (4-year program) at the University of Aberdeen on Parkinson’s disease (PD), immunology, and behavior. The major findings Ph.D. findings were the following: 1) the characterization of a small protein called HMGB1 as an inflammatory mediator in PD; 2) the motor and non-motor behavioral characterization of three neurotoxin based mouse models of PD, 3) the characterization of the innate immune response in PD through the toll-like receptor signaling pathways 4) evaluation of the effects of chronic systemic inflammation on both resident and infiltrating immune cells in the CNS. In 2012 Dr. Santoro attained his Pharm.D. in chemistry and pharmaceutical technology (5-year program) at the University of Calabria (Italy) during which he undertook an internship at the King’s College London (SGDP Centre) and worked for over a year on a rat model of stroke.

  • Ansuman Satpathy

    Ansuman Satpathy

    Assistant Professor of Pathology

    Current Research and Scholarly InterestsOur lab works at the interface of immunology, cancer biology, and genomics to study cellular and molecular mechanisms of the immune response to cancer. In particular, we are leveraging high-throughput genomic technologies to understand the dynamics of the tumor-specific T cell response to cancer antigens and immunotherapies (checkpoint blockade, CAR-T cells, and others). We are also interested in understanding the impact of immuno-editing on the heterogeneity and clonal evolution of cancer.

    We previously developed genome sequencing technologies that enable epigenetic studies in primary human immune cells from patients: 1) 3D enhancer-promoter interaction profiling (Nat Genet, 2017), 2) paired epigenome and T cell receptor (TCR) profiling in single cells (Nat Med, 2018), 3) paired epigenome and CRISPR profiling in single cells (Cell, 2019), and high-throughput single-cell ATAC-seq in droplets (Nature Biotech, 2019). We used these tools to study fundamental principles of the T cell response to cancer immunotherapy (PD-1 blockade) directly in cancer patient samples (Nature Biotech, 2019; Nat Med, 2019).

  • Birgitt Schuele

    Birgitt Schuele

    Associate Professor (Research) of Pathology

    BioBirgitt Schüle, MD, is an Associate Professor in the Department of Pathology at Stanford University School of Medicine. Her research focuses on medical genetics and stem cell modeling to uncover disease mechanisms and pathways involved in neurodegeneration in Parkinson's disease and related disorders. She is dedicated to developing novel therapeutic strategies that contribute to the advancement of precision medicine.
    Dr. Schüle obtained her medical training from the Georg-August University Göttingen and Medical University Lübeck, Germany, between 1993 and 2001. She earned her doctoral degree in medicine (Dr. med.) in neurophysiology from the Georg-August University Göttingen in 2001. During her neurology internship from 2001 to 2002 at the Medical University of Lübeck under the guidance of Prof. Christine Klein. Subsequently, she pursued a postdoctoral fellowship in human genetics with Prof. Uta Francke at Stanford University School of Medicine from 2003 to 2005.
    From 2005 to 2019, Dr. Schüle demonstrated leadership in spearheading critical clinical research programs and establishing essential biospecimen repositories for neurogenetics, translational stem cell research, and brain donation at the Parkinson's Institute and Clinical Center.
    Currently, Dr. Schüle serves as the Associate Core Leader, Neuropathology, within the Stanford Alzheimer Research Center (ADRC). Her contributions to ADRC include genetic characterization, biobanking, and the establishment of a human induced pluripotent stem cell and post-mortem leptomeninges tissue bank. These resources are shared with the data and tissue repositories at the National Institutes of Health (NIH), facilitating collaborative research and advancing our understanding of neurodegenerative diseases.
    Dr. Schüle's expertise and dedication in the field of neurodegeneration contribute significantly to the advancement of medical knowledge. She is recognized as a respected member of the scientific community, playing an important role in the pursuit of effective treatments and precision medicine approaches.

  • Robert W. Shafer

    Robert W. Shafer

    Professor (Research) of Medicine (Infectious Diseases) and, by courtesy, of Pathology

    Current Research and Scholarly InterestsMy group’s research is on the mechanisms and consequences of virus evolution with a focus on HIV therapy and drug resistance. We maintain a public HIV drug resistance database (http://hivdb.stanford.edu) as a resource for HIV drug resistance surveillance, interpreting HIV drug resistance tests, and HIV drug development. Our paramount goal is to inform HIV treatment and prevention policies by identifying the main factors responsible for the emergence and spread of drug resistance.

  • Hua Shan

    Hua Shan

    Professor of Pathology

    BioDr. Shan specializes in providing blood transfusion and apheresis treatment to patients with diverse medical problems. She has been practicing transfusion medicine for over twenty five years. Dr. Shan currently serves as the Medical Director of Transfusion Service at Stanford Medical Center. Dr. Shan has also been leading research and education programs in the fields of transfusion safety, optimizing clinical blood transfusion practice and blood availability.